# Endoscopic versus surgical drainage of the pancreatic duct in chronic pancreatitis: a prospective randomised trial

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>		
20/12/2005	No longer recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
20/12/2005	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
17/09/2008	Digestive System			

# Plain English summary of protocol

Not provided at time of registration

# Contact information

# Type(s)

Scientific

#### Contact name

Dr Djuna Cahen

#### Contact details

Academic Medical Center Meibergdreef 9 Amsterdam Netherlands 1105 AZ +31 (0)20 3474723 Djunacahen@hotmail.com

# Additional identifiers

**EudraCT/CTIS** number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

# Study information

#### Scientific Title

#### Acronym

**CEPAN** 

#### **Study objectives**

To compare endoscopic and surgical drainage of the pancreatic duct.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Ethics approval received from the local medical ethics committee

#### Study design

Randomised, active controlled, parallel group trial

#### Primary study design

Interventional

## Secondary study design

Randomised controlled trial

# Study setting(s)

Hospital

# Study type(s)

Treatment

#### Participant information sheet

# Health condition(s) or problem(s) studied

Chronic pancreatitis (CP)

#### **Interventions**

- 1. Surgical drainage: pancreaticojejunostomy
- 2. Endoscopic drainage: extracorporeal shock wave lithotripsy (ESWL) and/or pancreatic stenting

# **Intervention Type**

Other

#### Phase

**Not Specified** 

#### Primary outcome measure

Mean Izbicki pain score during follow-up

#### Secondary outcome measures

Clinical success:

- 1. Pain relief at end of FU
- 2. Complete (Izbicki pain score less than or equal to 10)
- 3. Partial (greater than 50% decrease, total score greater than 10)
- 4. Morbidity and mortality rate
- 5. Intervention rate
- 6. Hospital stay
- 7. Development of endo- and/or exocrine pancreatic insufficiency

#### Overall study start date

01/01/2000

#### Completion date

01/10/2004

# Eligibility

#### Key inclusion criteria

- 1. A diagnosis of CP, based on clinical symptoms in combination with morphological changes established by imaging studies (calcifications or ductal changes) and/or pancreatic functional insufficiency
- 2. A dominant obstruction of the pancreatic duct, demonstrated by presence of a stenosis and /or intraductal stones on magnetic resonance cholangiopancreatography (MRCP) and abdominal computed tomography (CT) scan, located left from the spine, with pre-stenotic ductal dilatation of at least 5 mm
- 3. Severe recurrent pancreatic pain with insufficient relieve by non-narcotic analgesics or requiring opiates

#### Participant type(s)

Patient

#### Age group

Adult

#### Sex

**Not Specified** 

#### Target number of participants

39

#### Key exclusion criteria

- 1. Age below 18 or over 80 years
- 2. Pancreatic head enlargement greater than 4 cm
- 3. Contra-indication for surgery; American Society of Anaesthesiologists (ASA) class 4, severe portal hypertension
- 4. Contra-indications for endoscopy: gastrectomy with Billroth II reconstruction, other pancreatitis related complications (bile duct stricture, pseudocyst) requiring surgery
- 5. Previous pancreatic surgery
- 6. Suspected pancreatic malignancy

- 7. Limited life expectancy (less than 2 years)
- 8. Pregnancy

## Date of first enrolment

01/01/2000

#### Date of final enrolment

01/10/2004

# Locations

#### Countries of recruitment

Netherlands

## Study participating centre Academic Medical Center

Amsterdam Netherlands 1105 AZ

# Sponsor information

## Organisation

Academic Medical Centre (AMC) (Netherlands)

## Sponsor details

Meibergdreef 9 Amsterdam Netherlands 1105 AZ

## Sponsor type

University/education

#### Website

http://www.amc.uva.nl/

#### **ROR**

https://ror.org/03t4gr691

# Funder(s)

# Funder type

#### Funder Name

AstraZeneca (The Netherlands) - unrestricted grant

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	15/02/2007		Yes	No